CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of non-Hodgkin lymphoma.
  
  PURPOSE STATEMENT
  By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with non-Hodgkin lymphoma.
  
  LEARNING OBJECTIVES

  • Identify patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) for whom CD79b-targeted therapy as a component of first-line treatment would be appropriate.
  • Understand published clinical research findings with CD19-targeted monoclonal antibodies in combination with immunomodulatory agents in treatment for DLBCL and follicular lymphoma (FL), and employ this information in patient education discussions.
  • Appraise the biological rationale for, available research findings with and current clinical role of CD19-targeted antibody-drug conjugates in therapy for patients with relapsed/refractory (R/R) DLBCL.
  • Evaluate published clinical research findings establishing the efficacy and safety of Bruton tyrosine kinase (BTK) inhibitors as a component of first-line therapy for mantle cell lymphoma (MCL), and assess the current and potential role of various BTK inhibitor-based strategies in the care of patients newly diagnosed with the disease.
  • Appreciate the biological rationale for, available data with and current clinical role of BTK inhibitors in treatment for patients with R/R MCL, and discern how these agents can be appropriately and safely integrated into routine practice.
  • Review published clinical research findings establishing the efficacy and safety of combined BTK inhibitor/anti-CD20 antibody therapy for R/R FL, and identify patients for whom treatment with available combinations would be appropriate.
  • Recognize the spectrum, frequency and severity of adverse events associated with various therapies commonly employed in the care of patients with NHL, and consider recommended approaches to prevent, ameliorate and manage resultant side effects.

  ACCREDITATION STATEMENT
  Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
  
  CREDIT DESIGNATION STATEMENT
  Audio Program: This educational activity for 2.25 contact hours is provided by RTP during the period of May 2025 to May 2026.
  
  This activity is awarded 2.25 ANCC pharmacotherapeutic contact hours.
  
  Video Program: This educational activity for 1.75 contact hours is provided by RTP during the period of May 2025 to May 2026.
  
  This activity is awarded 1.75 ANCC pharmacotherapeutic contact hours.
  
  ONCC/ILNA CERTIFICATION INFORMATION
  The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/ONS2025/NHL/ILNA.
  
  ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  FOR SUCCESSFUL COMPLETION
  Audio Program: This NCPD activity consists of an audio component. To receive credit, the participant should review the NCPD information, listen to the MP3s, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ONS2025/NHL/NCPD. The corresponding video program is available as an alternative at ResearchToPractice.com/ONS2025/NHL/Video.
  
  Video Program: This NCPD activity consists of a video component. To receive credit, the participant should review the NCPD information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ONS2025/NHL/Video/NCPD. The corresponding audio program is available as an alternative at ResearchToPractice.com/ONS2025/NHL.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Christopher Flowers, MD, MS
  Division Head, Division of Cancer Medicine
  Chair, Professor, Department of Lymphoma/Myeloma
  John Brooks Williams and Elizabeth Williams Distinguished University Chair in Cancer Medicine
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Consulting Agreements: AbbVie Inc, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Celgene Corporation, Denovo Biopharma, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Karyopharm Therapeutics; Contracted Research: 4D Pharma PLC, AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Alaunos Therapeutics, Allogene Therapeutics, Amgen Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Cellectis, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, Iovance Biotherapeutics, Janssen Biotech Inc, Kite, A Gilead Company, MorphoSys, Nektar Therapeutics, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Sanofi, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc, Xencor; Nonrelevant Financial Relationships: Burroughs Wellcome Fund, Cancer Prevention and Research Institute of Texas (CPRIT Scholar in Cancer Research), Eastern Cooperative Oncology Group, Foresight Diagnostics, National Cancer Institute, N-Power Medicine Inc, V Foundation.
  
  Manali Kamdar, MD, MBBS
  Associate Professor
  Clinical Director of Lymphoma Services
  Morton and Sandra Saffer Endowed Chair in Hematology Research
  Division of Hematology, Hematologic Malignancies
  University of Colorado Cancer Center
  Aurora, Colorado
  
  Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, BeiGene Ltd, Bristol Myers Squibb, Genentech, a member of the Roche Group; Contracted Research: Novartis; Data and Safety Monitoring Board/Committees: Celgene Corporation, Genentech, a member of the Roche Group.
  
  Robin Klebig, MSN, APRN, CNP, AOCNP
  Hematology Outpatient APP Supervisor
  Assistant Professor of Medicine
  Nurse Practitioner, Lymphoma Group
  Division of Hematology
  Mayo Clinic
  Rochester, Minnesota
  
  No relevant conflicts of interest to disclose.
  
  Caitlin Murphy, DNP, FNP-BC, AOCNP
  Clinical Nurse Practitioner
  Director of Advanced Practice Nursing
  Dana-Farber Cancer Institute
  Boston, Massachusetts
  
  Advisory Committees: Genmab US Inc, Seagen Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop NCPD activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.
  
  RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from ADC Therapeutics and AstraZeneca Pharmaceuticals LP.
  
  Release date: May 2025
  Expiration date: May 2026
  
  There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.